Presenting Companies
20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic.
AcuamarkDx has engineered the first-ever qPCR + methylation-based approach specifically optimized for highly accurate blood-based early-cancer signal detection at ultra-low abundance. qPCR is currently the tool of choice used by hospitals and clinics to diagnose a number of infectious diseases. Acuamark’s technology is high-throughput and highly scalable with low cost of goods sold, enabling more accurate blood-based early cancer detection while
generating high margins. Unlocking qPCR for reliable early cancer detection opens broad opportunity in the market. Effective, accessible and reliable early cancer detection will give patients an improved chance for a better outcome,
and eventually, broad adoption has the potential to reduce cancer deaths by 35-55%.
Applikate is a solutions-oriented company developing the next-generation tissue processing reagents, imaging hardware, and pathology software. The technology's combination of clearing histology and multiphoton microscopy achieves high-quality, in-depth histopathology data without the need for manual processes required of pathologists and their staff.
Apricity Health is a first-of-its-kind biotech platform company revolutionizing cancer drug discovery with real-time dynamic patient data lation. Our innovative Dynamic Precision™ platform combines unique human data, AI/ML with deep domain expertise to identify druggable resistance targets with blood-based patient-selection biomarkers to develop new medicines for treatment resistance smarter and faster.
Atmo Biosciences is a digital health business underpinned by a world-first ingestible gas-sensing capsule technology developed at RMIT University. When swallowed, the Atmo Gas Capsule can profile the gas biomarkers within the gut in real-time, leading to better diagnosis and assessment of treatments for gastrointestinal disorders, and the monitoring of microbiome function, leading to improved gut health and wellness.
Atzeyo Biosensors is revolutionizing cancer care by transforming early diagnosis and ongoing monitoring for patients. Our innovative point-of-care technology enables physicians to receive critical diagnostic results in real-time, right in the office. This eliminates the delays associated with traditional laboratory testing and empowers doctors to make faster, more informed decisions about patient care. Our proof-of-concept studies have demonstrated that Atzeyo’s biosensors offer superior detection capabilities compared to PCR testing. This advanced technology is not only more accurate but also more accessible. Designed as an easy-to-use, cost-effective device, it brings cutting-edge diagnostic capabilities to more healthcare settings, making it feasible for widespread adoption in clinics and hospitals alike.
AURA develops AI-enhanced software that integrates with existing ultrasound systems to provide precise guidance for breast cancer surgery. The technology detects existing biopsy clips during surgery, eliminating the need for additional pre-surgical localization devices like wires or seeds. This streamlines workflow, reduces costs, and improves patient experience. Future development will expand capabilities to include direct tumor visualization.
BioT is the infrastructure for medical device clouds, built right from the start. Its flexible, open, and secure cloud infrastructure keeps medical data safe while enabling you to build and offer new services and capabilities right out of the box. With BioT, you deliver SaaS-driven care and greater patient outcomes.
BMI OrganBank is developing medical devices to eliminate the waitlist for lifesaving organ transplants through better organ assessment, preservation and transport technologies. BMI developed their flagship product for kidney preservation in partnership with Duke University transplant surgeons and subsequently published promising preclinical data in a peer-reviewed journal. BMI has already engaged FDA and plans to initiate a clinical study in 2025. BMI recently completed due diligence and received investment from a large angel fund with deep medical device expertise (deal memo available to select investors).
Caelum Diagnostic Solutions is a seed-stage digital biopsy diagnostics company. Our CEO, Dr. Rachel Wellner, a breast surgical oncologist, has devised a technology which renders a biopsy evaluation in less than 10 minutes, with 94%-99% accuracy, while the patient is still on the procedure table. The Company’s initial target market is the breast cancer space but the technology has wider global application in other cancer indications.
Cairn Surgical, Inc. is a clinical stage company improving healthcare outcomes and economics with image-derived, patient-specific, 3D-printed, interventional guidance devices. The Company’s first product, the Breast Cancer Locator (BCL), is a breast cancer surgical guide. Initial single arm studies show significant improvements in clinical outcomes by reducing the positive surgical margin rate to near 0%. The Company is completing enrollment in a pivotal FDA approval trial and initiating commercial launch in EU.
Catheter Precision, Inc., a global medical device company, is dedicated to empowering healthcare providers to achieve optimal patient outcomes through the delivery of impactful and innovative technologies.
CathVision is a medical technology company that develops electrophysiology solutions centered around an innovative EP recording system and AI algorithm platform – the ECGenius System with CARDIALYTICS. Committed to empowering physicians to make more informed clinical decisions in the EP lab, CathVision is redefining the necessity of exceptional cardiac electrical signals to diagnose, characterize, and treat the most common heart rhythm disorders. For safety info, visit www.cathvision.com.
CorNeat Vision is a clinical-stage medical device company with a mission to advance human health. With a proven track record of restoring sight to the blind, our biomimetic implants leverage novel bio-integration technology and innovative concepts to develop groundbreaking solutions for unmet needs in ophthalmology and beyond. Our current products biomechanically integrate with the host tissue, offering safe, aesthetically pleasing, and long-lasting remedies for patients with corneal blindness and glaucoma. These products include: CorNeat KPro: An artificial cornea. CorNeat EverPatch: A synthetic tissue patch. CorNeat eShunt: An innovative glaucoma implant.
DiagMetrics, Inc. is pioneering innovative diagnostic solutions with a focus on non-invasive, real-time detection of respiratory diseases. Our flagship technology is a mask-based diagnostic including a proprietary semiconductor biosensor that detects viral, bacterial and patient-generated biomarkers in exhaled breath condensate, offering a convenient and rapid at-home and OTC diagnostic platform. Funded by the NIH’s RADx program, with a proven success in detecting Covid-19, DiagMetrics is advancing our technology for broader applications, including influenza and tuberculosis detection, as well as lung cancer screening. Our scalable platform has the potential to transform point-of-care diagnostics, making easy-to-use testing and remote patient monitoring accessible, affordable and practical.
DrNose has developed an Electronic Nose that senses the breath of a person to provide a non-intrusive, real time, early indicator of cancers and other chronic diseases. It is aimed to extend the traditional way of providing cancer diagnosis. This device consists of multiple smell sensors that can pick up complex chemical molecules and in combination enable us to diagnose a person’s likelihood of having certain diseases. 2 initial clinical trials have provided highly accurate results confirming that this smell sensor can pick up Breast Cancer and Lung Cancer. Finding the right combination of sensors and building the algorithm to do the diagnosis for each disease is the core of our technology.
Droplet Biosciences is pioneering the use of post-surgical lymphatic fluid to detect cancer that remains in the body in time to change what doctors do next. 90% of cancer first spreads via the lymphatic system. Droplet is the only company developing diagnostic tools using the highly differentiated biomarkers from this important sample source. Our patented approach delivers results that inform adjuvant decisions and is >2x more sensitive than blood. We have programs in head and neck, lung, bladder and renal cancers.
Using a minimally invasive procedure, the Efemoral Vascular Scaffold SystemTM is inserted into the leg and expanded inside the artery to restore a channel for blood flow to the foot. The scaffold is strong enough to hold the vessel open, is flexible enough to accommodate the complex skeletal motion of the leg, and elutes a drug to prevent scarring inside the vessel which leads to the need for repeat procedures. The scaffold is naturally absorbed by the body over time, thus leaving behind no permanent implant.
Heteron Biotechnologies is developing proprietary, non-invasive, disease-specific, autonomous, AI-enhanced, hand-held in vitro breath diagnostics for large markets of gastrointestinal, liver and metabolic diseases with unmet need for POC, OTC and for home-testing. Of the nine breath diagnostics under development, three have been validated with over 100 patients. Q-sub response confirmed that submissions will be 510K for the diagnostics with predicate product (hydrogen breathalyzer and H. Pylori detection breathalyzer) and DeNovo submission for the diagnostic without predicate (ammonia breathalyzer). The technology is patent-protected (8 issued patents and multiple pending patent applications) in the US, Europe and Asia and all products have very large addressable markets. Heteron is projecting to have six of its products through regulatory approval by the end of 2027, starting in early 2026 and the remaining three by 2028. The company is also developing wearable breath analyzers.
Inocras is a pioneering bioinformatics company that specializes in whole-genome sequencing (WGS) for cancer diagnostics. Founded by a team of MD, PhDs with advanced data science expertise, we are the first to offer a WGS-based diagnostic and MRD solutions on the market. Our proprietary algorithms enable precise analysis of complex cancer data, and our CAP/CLIA-certified lab in San Diego has successfully analyzed over 20,000 cancer cases. Supported by esteemed investors such as the Asan Foundation(Hyundai) and Samsung Ventures, Inocras is committed to advancing personalized medicine and transforming cancer care.
Integral has developed a screening platform for oral pathogens. Key pathogens have been demonstrated to trigger or exacerbate many systemic diseases including diabetes, rheumatoid arthritis, pre-term birth, and esophageal cancer. Our platform leverages Next Generation sequencing and advanced bioinformatics to screen for these pathogens using a non-invasive dental plaque sample. If detected, our algorithms provide care plan and treatment recommendations that enable preventative and personalized care. These biomarkers are not currently screened for despite their known correlation with many diseases – and Integral is here to change that.
iThera Medical leads the field of optoacoustic imaging (OAI) which utilizes the photoacoustic effect - absorption of light pulses resulting in acoustic signal emission - to visualize and quantify tissue biomarkers, in vivo, at high spatiotemporal resolution, at up to several centimeters depth. OAI promises to become a broadly applicable diagnostic technique, starting with assessing muscle perfusion, oxygenation and fibrosis in peripheral arterial disease and neuromuscular diseases.
Lumicell’s vision is to dramatically change the face of oncology so that every surgical patient goes home cancer-free. Our FDA-approved combination product, LumiSystem™, is comprised of LUMISIGHT™, a novel fluorescence imaging agent, and our imaging device, the Lumicell™ Digital Visualization System (DVS), which work together to find and guide the removal of residual cancer missed during the initial surgery. LumiSystem the first and only commercially available imaging solution capable of detecting cancer where and when it matters most, inside the breast cavity, in real-time. Additionally, the Company was also granted positive reimbursement status, further catalyzing adoption of this innovative technology. Driven by experienced medical device and life science executives and operators, the Company looks forward to this next stage of growth and clinical impact by continuing to deliver on its commercial launch into top-tier breast cancer centers as well as expand the the LumiSystem’s use across the range of solid tumors.
Magsorbeo Biomedical is a medical device development and manufacturing company founded by a team of industry veterans specializing in bioabsorbable metal implants. These fully absorbable implants are built from Magsorbeo's proprietary Curasorb alloy to improve surgery outcomes for patients, by restoring bone to its natural physiology after healing, before safely absorbing, thereby eliminating the long-term complications and implant removal surgeries often seen with permanent hardware left in the body. Curasorb is designed to safely eliminate the excessive trauma and healthcare costs caused by permanent implants while matching the performance and usability of titanium implants for the surgeon. Magsorbeo is taking a fast follower approach with superior products and a larger addressable market than the competition, leveraging the proven markets and defined FDA regulatory pathways with plans to launch a First in Human clinical in 2026.
Medical 21, Inc. is a medical device company, founded by Dr. Manny Villafaña (the Founder of St. Jude Medical and CPI/Guidant) and located in Minneapolis, MN. We are developing and intend to commercialize and market an artificial graft to bypass blockages in the heart.
Modulim is a pioneer in optical imaging solutions powered by spatial frequency domain imaging (SFDI) for noninvasive tissue and vascular assessment. Powered by SFDI, our Clarifi® Imaging System helps clinicians identify patients at-risk of complications due to microvascular dysfunction. The #ClarifiImagingSystem quantifies and maps five biomarkers of microvascular tissue oxygenation and perfusion. As a result, clinicians can quickly identify at-risk patients for earlier and more timely intervention so they may prevent complications such as diabetic foot ulcers and amputations. With its widespread adoption, our technology solutions have the potential to save limbs and lives, improve outcomes and reduce costs across the continuum of care by enabling early detection and intervention. Clarifi is affordable and easily integrated into a clinician’s practice. Clarifi imaging is supported by reimbursement (Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code (0061U). Our proprietary technology - SFDI - was invented by Modulim's founder and CTO David Cuccia, Ph.D., and his colleagues at UC Irvine’s Beckman Laser Institute. SFDI is a noninvasive tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared) to allow for deeper and layer-specific assessment of tissue oxygenation and hemoglobin. This unique technology deciphers the reflection, absorbance, and scattering of light in tissue.
Nano4Imaging is an innovation leader in developing software and devices for interventional MRI (iMRI) based on nanotechnology and artificial intelligence. The company offers a groundbreaking technology platform — navigation software, MRI markers, and devices — enabling MRI for endovascular interventions in real-time. The advantages over X-ray/CT imaging are more precise and safer interventions. Emery Glide, the first MRI-compatible guidewire, has been FDA-approved and successfully used to treat over 200 patients.
Neurovascular Research and Design develops an intraoperative monitoring platform that automatically and continuously monitors the functional integrity of neurovascular structures that are at surgical risk during high-risk surgery, improving surgical outcomes and maintaining the patient's quality of life. Our transformative approach to intraoperative monitoring increases access and availability, improves reliability, and significantly reduces costs.
Novuson has developed the first-in-class Direct Therapeutic Ultrasound surgical instruments for safer, more precise surgeries. Novuson technology doesn't burn tissue or create smoke, which is why it is safer and more precise. Novuson's technology is a razor/razor blade model (generator/handset) and initially will be launched in ambulatory surgical centers.